Coronavirus Is Likely to Generate Telltale Signs, Fauci Says
(Bloomberg) -- Most people who've had the coronavirus probably develop markers of the infection, according to Anthony Fauci, the scientist who's leading the U.S. response to the pandemic.
Fauci, director of the National Institute of Allergy and Infectious Diseases, said it would be “extremely unusual” if patients did not develop antibodies, which often bestow immunity on people who've been infected with a virus. Other experts have cast doubt on whether this happens in everyone with the new coronavirus, fueling concerns about the insidious nature of the illness.
“I'd be careful about saying people who get infected don't have any antibodies,” Fauci said in an interview. “It would be almost unprecedented.”
The dependable appearance of antibodies following Covid-19 infections would be highly reassuring as governments move to restart economies from lockdowns. Tests for them can show who's been infected by the pathogen and how far it's spread -- and, potentially, how many people have developed immunity that could allow them to work in virus-exposed jobs with less risk of illness.
Scientists from China said in April that they couldn't find signs of protective antibodies in about 6% of the 175 recovered patients they tested. Officials at the World Health Organization have said the nature of any immune response remains unclear.
Different Responses
The same study that found patients with no antibodies found others with significant responses. “Right now the information is mixed,” Maria Van Kerkhove, Covid-19 technical lead at the WHO, said at a press briefing in April. “We need much more information from recovered patients.”
The unreliability of antibody tests has stymied the national responses of the U.K. and other countries that sought to use them to determine when it's safe to relax social distancing measures, allow stores to open and end lockdowns. Millions of tests purchased by European countries were found incapable of determining who's been infected. Only a few antibody tests have been validated by the U.S. Food and Drug Administration, Fauci pointed out.
“Before anybody tells me that there is no antibody, I want to make sure that it was measured with a validated test,” he said.
An email to the scientists at Fudan University in Shanghai who led the Chinese study wasn't immediately returned. The paper appeared online before it was published or peer-reviewed.
Fauci stopped short of saying he doubted the findings of patients without antibodies, saying that he hasn't seen the data. Scientists need to focus on how and when antibodies to the virus are produced, how protective they are, and how long that defense lasts, Fauci said.
“Those are all open questions in my mind,” he said.
Targeted Proteins
Antibodies are proteins that latch onto viruses at key sites to prevent them from entering cells and tissues. They're highly individualized to the viruses and other germs that they target, and key to most successful vaccines because they act early in an infection. Some of the leading experimental vaccines against Sars-CoV-2 aim primarily at another branch of the immune response, called T-cells, rather than antibodies.
The presence of specific antibodies can show whether a person has been exposed to a virus months or even years afterward.
Another kind of test looks for the actual presence of the virus, and indicates that a person is currently infected and capable of spreading it. That's key to the U.S. effort to reopen businesses and ease restrictions on activities, Fauci said.
After initial missteps, the U.S. has made “extraordinary progress” in increasing access to testing, following an administration blueprint that was released earlier this week, he said.
The U.S. will provide both strategic direction and technical assistance regarding the best use of available testing technology, and partner with states to ramp up testing for the virus, he said.
“That's what the plan is,” he said. “Whether it will work remains to be seen, but I think it will certainly be much, much better than it has been in the past.”
©2020 Bloomberg L.P.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.